Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,823,738 papers from all fields of science
Search
Sign In
Create Free Account
sipuleucel-T
A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
13 relations
250 ML sipuleucel-T 200000 CELLS/ML Injection
250 ML sipuleucel-T 200000 CELLS/ML Injection [Provenge]
ACPP protein, human
Antigen Sensitization
Expand
Narrower (2)
APC 8015
Provenge
Broader (1)
Tissue Extracts
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Largest Race-Based Survival Advantage to Date Seen in Men Receiving Sipuleucel-T for Prostate Cancer
J. Kling
2019
Corpus ID: 196552903
A subanalysis of the PROCEED trial showed a surprisingly high survival advantage for a particular race of men receiving…
Expand
2017
2017
Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC).
L. Fong
,
E. Small
,
+7 authors
C. Drake
2017
Corpus ID: 78358206
143Background: Sip-T, an FDA-approved autologous immunotherapy for pts with asymptomatic or minimally symptomatic metastatic…
Expand
2014
2014
The Targeting of IDO-Mediated Immune Escape in Cancer
T. Z. Iversen
,
M. Andersen
,
I. Svane
2014
Corpus ID: 207791935
The era of immunotherapies was unleashed in 2010 with the Food and Drug Administration (FDA) approval of the first therapeutic…
Expand
Review
2014
Review
2014
Survival With Bone Metastases Resulting From Castration-Resistant Prostate Cancer Table 1 Survival Advantages in Phase 3 Trials of Agents Used or Under Investigation in Metastatic Castration…
J. McCain
2014
Corpus ID: 24564365
INTRODUCTION Bone metastases from prostate cancer are a substantial source of morbidity and mortality. Prostate cancer caused…
Expand
2014
2014
A Novel Tumor Antigen and Foxp3 Dual-Targeting Tumor Cell Vaccine Enhances the Immunotherapy in a Murine Model of Renal Cell Carcinoma
Li Shen
2014
Corpus ID: 29043116
Abstract : During the past year I have generated Foxp3-over expressing RENCA cells, as the source of candidate dual targeting…
Expand
2013
2013
Perspectives Targeting dendritic cells — why bother ?
M. Kreutz
,
P. Tacken
,
C. Figdor
2013
Corpus ID: 40340921
Classic vaccines are among the most cost-effective public health interventions and provide a good example of effective…
Expand
2012
2012
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
P. Kantoff
,
C. Higano
,
E. Small
,
J. Whitmore
,
M. Frohlich
,
P. Schellhammer
Journal of the National Cancer Institute
2012
Corpus ID: 38443096
Vol. 104, Issue 18 | September 19, 2012 References 1. Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of…
Expand
2012
2012
Recent successes of cancer immunotherapy: a new dimension in personalized medicine?
C. Caux
,
L. Zitvogel
Targeted oncology
2012
Corpus ID: 24334796
Until recently, cancer therapy was limited to “debulking approaches” including surgery, chemo–radio- and hormono-therapy and…
Expand
Review
2012
Review
2012
Immuntherapie beim metastasierten Prostatakarzinom – brauchen wir diese wirklich?
A. Heidenreich
Der Urologe
2012
Corpus ID: 2837288
ZusammenfassungDie Therapie des progredienten und metastasierten kastrationsresistentes Prostatakarzinom (KRPCA) befindet sich…
Expand
2008
2008
The special treatment
R. Osborne
Nature Biotechnology
2008
Corpus ID: 12515030
The special protocol assessment introduced only six years ago by the US Food and Drug Administration (FDA) to facilitate clinical…
Expand